Skip to content

Inhibrx Biosciences, Inc.

INBX· NasdaqCore metricsCIK 2007919

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -3.39%
Market cap
$1.30B
14.77M shares
Filings
162
$2.00M
Q3 2026+550.0% FY25 yoy
-$38.73M
Q3 2026N/M FY25 yoy
-$31.74M
Q3 2026N/M FY25 yoy
-$102.58M
Q3 2026derivedN/M FY25 yoy
-$2.46
Q3 2026N/M FY25 yoy
$199.47M
Q3 2026−18.6% FY25 yoy
$1.30B
—
996.2×
—
-10.02%
—

FY2025 figures · derived

Price

$87.69+12.94%+$10.05past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$1.30MFY 2025
$1.80M0FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$1,300,000reported
FY 20242024-12-31$200,000reported
FY 20232023-12-31$1,800,000reported

Segments

Products
Revenue by Products, FY2023 to FY2025FY2023License fee revenue · FY2023 · $1.80MLicense fee revenue · FY2023 · $1.80MFY2024License fee revenue · FY2024 · $200.00KLicense fee revenue · FY2024 · $200.00KFY2025License fee revenue · FY2025 · $1.30MLicense fee revenue · FY2025 · $1.30M
LineFY2025ShareChange
License fee revenue$1.30M100%+550.0%
License fee revenue$1.30M100%+550.0%
Total$1.30M

From the 10-K filed Mar 19, 2026INBX

Biological products, except diagnostic substances

Inhibrx Biosciences, Inc. is the 78th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Inhibrx Biosciences, Inc. · CIK 2007919 · Engraved from SEC EDGAR